Algernon Pharmaceuticals CEO Christopher Moreau joined Steve Darling from Proactive to share news the Company has decided to form a private subsidiary to advance its Psychedelic DMT Stroke Program.

Mr. Moreau explains that AGN NeuroScience will stay private until it has progressed through to the completion of a Phase 2a stroke study planned to begin in Q4 of 2023. Following that, the company will review and consider a potential direct IPO listing onto the NASDAQ.